Allogeneic bone marrow-derived mesenchymal stem cells
1 paper3 findings
- 1 lab in 1 country
- Funder: The Michael J. Fox Foundation for Parkinson's Research
- Human trial1
Outcomes
3Blood urea nitrogen
no changein humans1
1 study
Blood urea nitrogen
no changein humans1
Allogeneic bone marrow-derived mesenchymal stem cells have no effect on blood urea nitrogen in humans.
“BUN levels did not differ significantly between treatment and placebo groups.”
Human trialParkinson's disease with baseline eGFR > 60 mL/min/1.73 m288 weeksn = 44
Stem cell research & therapySep 24, 2025
Serum creatinine
downin humans1
1 study
Serum creatinine
downin humans1
Allogeneic bone marrow-derived mesenchymal stem cells decrease serum creatinine in humans (-0.12 mg/dL at weeks 40 and 88 vs placebo).
“SCr decreased by -0.12 mg/dL at both weeks 40 (PP: 93.9%) and 88 (PP: 86.2%) in the three-infusion group versus placebo”
Human trialParkinson's disease with baseline eGFR > 60 mL/min/1.73 m2three infusions at 18-week intervalsweeks 40 and 88n = 16
Stem cell research & therapySep 24, 2025
eGFR
upin humans1
1 study
eGFR
upin humans1
Allogeneic bone marrow-derived mesenchymal stem cells increase eGFR in humans (+3.29 mL/min/1.73 m2 average annual increase vs -2.92 decline in placebo).
“The three-infusion group (N = 16) showed an average annual eGFR increase of 3.29 mL/min/1.73 m2, versus declines of -1.46 and -2.92 in the two-infusion (N = 14) and placebo (N = 15) groups.”
Human trialParkinson's disease with baseline eGFR > 60 mL/min/1.73 m2three infusions at 18-week intervals88 weeksn = 16
Stem cell research & therapySep 24, 2025